Ba Da Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ba Da Yun has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Jong Kook Park
Department of Biomedical Science, Hallym University, Chuncheon, Republic of Korea
1 shared publication - Mun Gyu Song
Department of Biomedical Science, Research Institute for Bioscience & Biotechnology, Hallym University, Chunchon 24252, Korea
1 shared publication - Seung Wan Son
Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University, Chunchon 24252, Korea
1 shared publication
Latest Publications
- Open Access
- 7 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (3) , 263
Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer
Therapeutic resistance is an inevitable impediment towards effective cancer therapies. Evidence accumulated has shown that the signaling pathways and related factors are fundamentally responsible for therapeutic resistance via regulating diverse cellular events, such as epithelial-to-mesenchymal transition (EMT), stemness, cell survival/apoptosis, autophagy, etcetera. Noncoding RNAs (ncRNAs) have been identified as essential cellular components in gene regulation. The expression of ncRNAs is altered in cancer, and dysregulated ncRNAs participate in gene regulatory networks in pathological contexts. An in-depth understanding of molecular mechanisms underlying the modulation of therapeutic resistance is required to refine therapeutic benefits. This review presents an overview of the recent evidence concerning the role of human ncRNAs in therapeutic resistance, together with the feasibility of ncRNAs as therapeutic targets in pancreatic cancer.
- 7 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (3) , 263
Open AccessNoncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer
Therapeutic resistance is an inevitable impediment towards effective cancer therapies. Evidence accumulated has shown that the signaling pathways and related factors are fundamentally responsible for therapeutic resistance via regulating diverse cellular events, such as epithelial-to-mesenchymal transition (EMT), stemness, cell survival/apoptosis, autophagy, etcetera. Noncoding RNAs (ncRNAs) have been identified as essential cellular components in gene regulation. The expression of ncRNAs is altered in cancer, and dysregulated ncRNAs participate in gene regulatory networks in pathological contexts. An in-depth understanding of molecular mechanisms underlying the modulation of therapeutic resistance is required to refine therapeutic benefits. This review presents an overview of the recent evidence concerning the role of human ncRNAs in therapeutic resistance, together with the feasibility of ncRNAs as therapeutic targets in pancreatic cancer.